Comparative Pharmacology
Head-to-head clinical analysis: ISOPTO CETAMIDE versus OCUSULF 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPTO CETAMIDE versus OCUSULF 10.
ISOPTO CETAMIDE vs OCUSULF-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, disrupting folic acid synthesis and thereby inhibiting bacterial growth.
Sulfacetamide sodium is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and exerting bacteriostatic effects.
1-2 drops into conjunctival sac every 2-3 hours initially, then taper as infection resolves. Ophthalmic suspension (10% or 30%).
Instill 1 drop into the affected eye(s) every 4 hours while awake.
None Documented
None Documented
Terminal elimination half-life of sodium sulfacetamide is 7-12 hours in normal renal function; prolonged in renal impairment.
1.5–2.5 hours (terminal) in adults; prolonged to 3–5 hours in renal impairment (CrCl <30 mL/min).
Primarily renal (sodium sulfacetamide excreted unchanged in urine, ~85% within 24 hours). Minor biliary/fecal elimination.
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic